So, you don't believe in the method and have sold the rest of your holding of ORMP. Does that mean, that it was your last contibution to the message board? Thanks for the more serious contibutions. However, I think that investors should decide for themself how they are going to evaluate the results. I do not have any specific knowlege of the Zacks analyst, but he or she does not share your opinion.
The volume was only 1000 shares and he has handed in a SEC filling. So if someone think it is a problem, it absolutely most be a very, very, very minor problem :) At a day when many small holding investors seemed to find all kind of horror stories, I find it super, that the CEO by his SEC filling signalized, that he had not sold out of his position,
I think it's all right to express scepticism regarding the possibility that ORMP will succed, but I do not find it all right to call it a scam or fraud. I think ORMP like Emispher is trying to develop and test a method to take different kinds of medical treatments by pills instead of injections. Novo seems still to believe in EMIS' method, and is partner in the ph IIII clinical test including 9000 patients. In ny opinion Novo is a very serious company in diabetis treatment. Of couse, they may be wrong, but if a pill treatment is impossible (scam or fraud) I don't think, that Novo would participate in the EMIS project.
Thanks for sharing your knowledge. I have still a positive return on ny ORMP investment, and have decided to wait and see and hold ny position,
I think most people, who have followed the company do not expect disappointing top line data. The security of the treatment seems to be confirmed in different clinical tests. The only uncertainty is how significant the effect will be compared to the placebo group. I expect an effect in the level 25-35 % higher than placebo treatment.
What do you mean by significant? Quote from Zacks press note regarding their price taget raise to $ 30: "This study showed a statistically significant decrease in the primary endpoint, pooled night-time glucose mean percentage change of 6.47% from run-in, between placebo and active cohorts (p=0.0268). "